OBI Pharma, Inc.(TW:4174)
NT$60.50+5.50 (+10.00%)
TW:4174
OBI Pharma, Inc. financials statements
NT$60.50
At close:+5.50 (+10.00%)
OBI Pharma, Inc. (4174) Ratios
OBI Pharma, Inc. Ratios
TW:4174's free cash flow for Q2 2026 was NT$-290.76M. For the 2026 fiscal year, TW:4174's free cash flow was decreased by NT$-1.77M and operating cash flow was NT$-288.99M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Mar 24 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.51 | 8.34 | 19.92 | 22.76 | 8.72 |
| Quick Ratio | 4.45 | 8.27 | 19.92 | 22.76 | 8.72 |
| Cash Ratio | 2.17 | 4.20 | 5.67 | 21.44 | 7.68 |
| Solvency Ratio | -2.62 | -2.51 | -1.23 | -3.32 | -2.44 |
| Operating Cash Flow Ratio | -5.76 | -4.45 | -10.42 | -7.32 | -3.25 |
| Short-Term Operating Cash Flow Coverage | -16.53 | -52.32 | -146.22 | -71.34 | -152.07 |
| Net Current Asset Value | NT$ 883.95M | NT$ 2.61B | NT$ 2.51B | NT$ 4.54B | NT$ 2.24B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.15 | 0.09 | 0.09 | 0.04 | 0.07 |
| Debt-to-Equity Ratio | 0.27 | 0.13 | 0.13 | 0.05 | 0.11 |
| Debt-to-Capital Ratio | 0.21 | 0.12 | 0.12 | 0.05 | 0.10 |
| Long-Term Debt-to-Capital Ratio | 0.02 | 0.01 | 0.00 | 0.00 | 0.01 |
| Financial Leverage Ratio | 1.81 | 1.48 | 1.47 | 1.43 | 1.65 |
| Debt Service Coverage Ratio | -14.32 | -49.45 | -52.44 | -61.76 | -138.71 |
| Interest Coverage Ratio | -165.14 | -222.66 | -263.30 | -479.47 | -457.73 |
| Debt to Market Cap | 0.04 | 0.01 | 0.00 | 0.01 | 0.00 |
| Interest Debt Per Share | 8.04 | 4.42 | 4.44 | 2.26 | 2.95 |
| Net Debt to EBITDA | 0.13 | 0.54 | 0.39 | 2.70 | 1.46 |
| Profitability Margins | |||||
| Gross Profit Margin | -132.36% | -121.69% | -176.89% | -852.13% | -136.32% |
| EBIT Margin | -3702.58% | -3965.60% | -3050.90% | -40609.25% | -9260.89% |
| EBITDA Margin | -3314.77% | -3611.00% | -2451.72% | -35374.49% | -8108.78% |
| Operating Profit Margin | -3702.58% | -3783.67% | -5029.70% | -40609.25% | -9260.89% |
| Pretax Profit Margin | -3857.41% | -3982.59% | -3070.00% | -40693.95% | -9281.13% |
| Net Profit Margin | -3504.61% | -3685.55% | -2518.65% | -40316.79% | -9151.34% |
| Continuous Operations Profit Margin | -3852.76% | -3976.91% | -3046.91% | -40316.79% | -9151.34% |
| Net Income Per EBT | 90.85% | 92.54% | 82.04% | 99.07% | 98.60% |
| EBT Per EBIT | 104.18% | 105.26% | 61.04% | 100.21% | 100.22% |
| Return on Assets (ROA) | -60.00% | -40.86% | -18.67% | -28.63% | -38.29% |
| Return on Equity (ROE) | -108.70% | -60.56% | -27.49% | -41.00% | -63.25% |
| Return on Capital Employed (ROCE) | -70.63% | -45.25% | -38.38% | -29.83% | -41.79% |
| Return on Invested Capital (ROIC) | -66.71% | -44.42% | -37.67% | -29.27% | -40.63% |
| Return on Tangible Assets | -60.84% | -41.32% | -18.92% | -30.38% | -42.02% |
| Earnings Yield | -57.82% | -33.81% | -13.23% | -24.90% | -15.24% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.88 | 2.70 | 1.11 | 0.17 | 0.81 |
| Payables Turnover | 138.18 | 47.91 | 148.83 | 39.21 | 84.50 |
| Inventory Turnover | 7.38 | 5.01 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.06 | 0.05 | 0.03 | 0.00 | 0.02 |
| Asset Turnover | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.03 | 0.02 | 0.01 | 0.00 | 0.01 |
| Cash Conversion Cycle | 463.42 | 200.34 | 325.15 | 2181.23 | 448.12 |
| Days of Sales Outstanding | 416.64 | 135.13 | 327.60 | 2190.54 | 452.44 |
| Days of Inventory Outstanding | 49.43 | 72.83 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 2.64 | 7.62 | 2.45 | 9.31 | 4.32 |
| Operating Cycle | 466.06 | 207.96 | 327.60 | 2190.54 | 452.44 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -30.72 | -15.70 | -14.43 | -14.58 | -10.59 |
| Free Cash Flow Per Share | -31.46 | -16.72 | -15.38 | -17.29 | -13.03 |
| Dividend Paid and CapEx Coverage Ratio | -41.85 | -15.34 | -15.28 | -5.39 | -4.34 |
| Capital Expenditure Coverage Ratio | -41.85 | -15.34 | -15.28 | -5.39 | -4.34 |
| Operating Cash Flow Coverage Ratio | -3.92 | -3.63 | -3.30 | -6.56 | -3.63 |
| Operating Cash Flow to Sales Ratio | -34.49 | -29.25 | -39.78 | -343.81 | -56.71 |
| Free Cash Flow Yield | -58.25% | -28.59% | -22.26% | -25.17% | -11.62% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.73 | -2.96 | -7.56 | -4.02 | -6.56 |
| Price-to-Sales (P/S) Ratio | 60.62 | 109.00 | 190.44 | 1619.39 | 600.49 |
| Price-to-Book (P/B) Ratio | 1.88 | 1.79 | 2.08 | 1.65 | 4.15 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.72 | -3.50 | -4.49 | -3.97 | -8.61 |
| Price-to-Operating Cash Flow Ratio | -1.76 | -3.73 | -4.79 | -4.71 | -10.59 |
| Price-to-Earnings Growth (PEG) Ratio | -0.03 | -0.03 | 0.16 | 0.00 | -0.44 |
| Enterprise Value Multiple | -1.70 | -2.48 | -7.38 | -1.88 | -5.95 |
| Enterprise Value | 3.31B | 5.61B | 7.51B | 3.13B | 9.05B |
| EV to EBITDA | -1.70 | -2.48 | -7.38 | -1.88 | -5.95 |
| EV to Sales | 56.46 | 89.43 | 180.85 | 665.45 | 482.28 |
| EV to Free Cash Flow | -1.60 | -2.87 | -4.27 | -1.63 | -6.91 |
| EV to Operating Cash Flow | -1.64 | -3.06 | -4.55 | -1.94 | -8.50 |
| Tangible Book Value Per Share | 40.73 | 40.74 | 42.61 | 51.81 | 34.56 |
| Shareholders’ Equity Per Share | 28.72 | 32.66 | 33.24 | 41.71 | 27.03 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| Revenue Per Share | 0.89 | 0.54 | 0.36 | 0.04 | 0.19 |
| Net Income Per Share | -31.22 | -19.78 | -9.14 | -17.10 | -17.10 |
| Tax Burden | 0.91 | 0.93 | 0.82 | 0.99 | 0.99 |
| Interest Burden | 1.04 | 1.00 | 1.01 | 1.00 | 1.00 |
| Research & Development to Revenue | 29.24 | 31.41 | 40.84 | 376.32 | 77.22 |
| SG&A to Revenue | 2.58 | 5.21 | 7.68 | 65.75 | 12.83 |
| Stock-Based Compensation to Revenue | 0.54 | 1.02 | 2.87 | 31.63 | 2.88 |
| Income Quality | 0.89 | 0.73 | 1.30 | 0.84 | 0.61 |
Currency in TWD
